List today: Pharming Group N.V. PHAR: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing nearly 7% over the last 60 days. Pharming Group N.V.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect ...

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary ...

A teenager who lost her mother, aunt and uncle to a genetic condition has become the first person in Europe to receive a ...

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an on-time approval.

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares ...

KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...

Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second ...

A Cambridge teen has become the first person in Europe to receive a “life-changing” drug for a rare genetic condition which contributed to the early deaths of her mother, aunt, uncle and ...

Between 40 to 50 people in England are known to have APDS. The list price for leniolisib is £352,000 per person per year but the company Pharming has agreed a discount for the NHS. The team that ...